Latest Breaking News On - Corvus pharmaceuticals - Page 4 : comparemela.com

Stock Analysts' Updated EPS Estimates for April 1st (ACHV, ACRV, ADSK, ADTH, AFG, AFMD, AGO, AGS, AIG, ALKS)

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Investment Analysts' Updated EPS Estimates for March 27th (ADBE, APLS, BABA, CHKP, CLSK, CMCX, CRVS, DPLM, ECOR, ENV)

Investment Analysts’ updated eps estimates for Wednesday, March 27th: Adobe (NASDAQ:ADBE) had its buy rating reaffirmed by analysts at Mizuho. The firm currently has a $680.00 price target on the stock. Apellis Pharmaceuticals (NASDAQ:APLS) had its neutral rating reiterated by analysts at Mizuho. Mizuho currently has a $60.00 target price on the stock. Alibaba Group […]

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the.

Reviewing Aquestive Therapeutics (NASDAQ:AQST) and Corvus Pharmaceuticals (NASDAQ:CRVS)

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation. Analyst Recommendations This is a summary of […]